Tumor-Homing iRGD Peptide Dramatically Improves Camptothecin's Ability to Reach and Kill Colon Cancer Cells
Conjugating the tumor-homing peptide iRGD to camptothecin dramatically improved drug penetration into colon cancer cells and tumor accumulation in mice, suppressing tumor growth more effectively than the free drug.
Quick Facts
What This Study Found
iRGD-camptothecin conjugate showed superior cell penetration, greater colon cancer cell killing at micromolar concentrations, higher tumor accumulation, and enhanced antitumor effects compared to unconjugated camptothecin in both in vitro and in vivo models.
Key Numbers
The conjugate was linked via a heterobifunctional linker. Both in vitro and in vivo studies showed improved tumor targeting.
How They Did This
In vitro: synthesized iRGD-CPT conjugate with heterobifunctional linker, tested penetration and viability in human colon cancer cells. In vivo: evaluated tumor distribution and antitumor efficacy in a mouse colon cancer model.
Why This Research Matters
Camptothecin is a potent anticancer agent but suffers from poor tumor penetration and off-target toxicity. Using iRGD peptide for targeted delivery could improve the therapeutic index, delivering more drug to tumors while reducing systemic side effects.
The Bigger Picture
Tumor-homing peptides like iRGD represent a growing strategy for improving cancer drug delivery. By exploiting the unique biology of tumor blood vessels and cancer cell surfaces, peptide-drug conjugates can achieve targeted delivery that conventional chemotherapy cannot.
What This Study Doesn't Tell Us
Single cancer type (colon cancer) tested. Mouse xenograft models don't fully replicate human tumor biology. The stability and pharmacokinetics of the conjugate in humans are unknown. Comparison was only to free drug, not to other targeting strategies.
Questions This Raises
- ?Would iRGD-CPT be effective against other cancer types that express integrin targets?
- ?How does the toxicity profile of the conjugate compare to free camptothecin in animal models?
- ?Could iRGD be used to deliver other problematic anticancer compounds?
Trust & Context
- Key Stat:
- Enhanced tumor accumulation iRGD-CPT conjugate showed higher tumor tissue distribution and greater antitumor effects than unconjugated camptothecin in mice
- Evidence Grade:
- Preliminary evidence from in vitro and in vivo preclinical studies. Demonstrates proof of concept but lacks clinical data.
- Study Age:
- Published in 2024. Advances the peptide-drug conjugate field for cancer therapy.
- Original Title:
- Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy.
- Published In:
- European journal of medicinal chemistry, 265, 116050 (2024)
- Authors:
- Singh, Tejinder, Kim, Tae Wan, Murthy, Akula S N, Paul, Mohuya, Sepay, Nasim, Jeong Kong, Hye, Sung Ryu, Jae, Rim Koo, Na, Yoon, Sujeong, Song, Keon-Hyoung, Jun Baek, Moo, Jeon, Seob, Im, Jungkyun
- Database ID:
- RPEP-09281
Evidence Hierarchy
Frequently Asked Questions
What is iRGD and how does it find tumors?
iRGD is a small cyclic peptide that binds to integrins (proteins abundant on tumor blood vessels and cancer cells). After binding, it triggers a cell-penetration pathway that actively transports the attached drug deep into tumor tissue.
Why not just use camptothecin directly?
Camptothecin is effective at killing cancer cells but doesn't preferentially go to tumors — it distributes throughout the body, causing side effects. By attaching it to iRGD, more drug reaches the tumor and less goes to healthy tissue, potentially making treatment more effective with fewer side effects.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09281APA
Singh, Tejinder; Kim, Tae Wan; Murthy, Akula S N; Paul, Mohuya; Sepay, Nasim; Jeong Kong, Hye; Sung Ryu, Jae; Rim Koo, Na; Yoon, Sujeong; Song, Keon-Hyoung; Jun Baek, Moo; Jeon, Seob; Im, Jungkyun. (2024). Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy.. European journal of medicinal chemistry, 265, 116050. https://doi.org/10.1016/j.ejmech.2023.116050
MLA
Singh, Tejinder, et al. "Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy.." European journal of medicinal chemistry, 2024. https://doi.org/10.1016/j.ejmech.2023.116050
RethinkPeptides
RethinkPeptides Research Database. "Tumor-homing peptide iRGD-conjugate enhances tumor accumulat..." RPEP-09281. Retrieved from https://rethinkpeptides.com/research/singh-2024-tumorhoming-peptide-irgdconjugate-enhances
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.